FDA approves new delivery system for IV antibiotic

June 1, 2006

The FDA recently approved a new delivery system for the antibioticcefoxitin, which is indicated for the treatment of urinary tractinfections, gynecologic infections (eg, pelvic inflammatorydisease), and a number of other common infections.

The FDA recently approved a new delivery system for the antibiotic cefoxitin, which is indicated for the treatment of urinary tract infections, gynecologic infections (eg, pelvic inflammatory disease), and a number of other common infections.

The Duplex Drug Delivery System is now the only ready-to-use IV drug delivery system available for cefoxitin therapy in the United States, according to its manufacturer, B. Braun Medical Inc. Its FDA approval follows supply shortages caused by the recent discontinuation of Baxter Healthcare’s cefoxitin for injection (Mefoxin).

B. Braun said it is currently accepting calls to assist customers affected by the supply shortage. The company can be reached at 800-227-2862.